LEXX Lexaria Bioscience
- 2.3000
- -0.0100-0.43%
Lexaria Bioscience News
Positive Partial 12-Week Blood Sugar Results From Lexaria's GLP-1 Diabetes Animal Study
Express News | Lexaria Bioscience Corp: Positive Partial 12-Week Body Weight Results From Lexaria’s GLP-1 Diabetes Animal Study
Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Lexaria Bioscience Launches Human Study of DehydraTECH-Processed Tirzepatide
Lexaria Updates Current GLP-1 Market
Lexaria Bioscience Welcomes New CFO Amid Growth
Lexaria Appoints Michael Shankman as Chief Financial Officer
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Express News | Wayne W. Boos Reports 3.795% Stake in Lexaria Bioscience as of Aug 31 Vs 5.79% as of July 31 - SEC Filing
Lexaria Bioscience Ushers in New Leadership and Focus
Lexaria Bioscience Taps InVivo Therapeutics CFO Richard Christopher As New CEO
Express News | Lexaria Bioscience- Chris Bunka, CEO, Stepping Aside for Appointment of Richard Christopher as New CEO
Lexaria Bioscience Advances Drug Delivery With PharmaCO Partnership
12 Health Care Stocks Moving In Monday's Intraday Session
Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events
Express News | Lexaria Bioscience: Dehydratech-Processed Rybelsus Evidenced Trend Toward Higher Overall Absorption Vs Rybelsus Not Processed With Dehydratech
First Results From Lexaria's Second GLP-1 Human Pilot Study
Express News | Lexaria Bioscience Corp -Dehydratech-Liraglutide Is Outperforming Dehydratech-Semaglutide
Express News | Lexaria Bioscience - May Issue, Sell, From Time to Time, up to $20 Mln Shares of Common Stock
Analysis
Price Target
No Data
No Data